EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

LSD1-based dual-target inhibitors as emerging anticancer agents: pharmacological perspectives and SAR exploration

Pitam Ghosh, Ryena Dhir, Dinki Sharma, Subhadip Maity, Sanjay Kumar Bharti, Vivek Asati

Future Medicinal Chemistry · 18.08.2026 · 18 (16) · 2203-2225

DOI: 10.1080/17568919.2026.2699684 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Medicinal Chemistry, online erschienen am 11.07.2026. Verfasst von Pitam Ghosh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India. Hauptthemen laut MEDLINE: Histone Demethylases, Antineoplastic Agents, Enzyme Inhibitors, Neoplasms. Die Arbeit nennt 137 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

LSD1 is a key epigenetic eraser that demethylates the histone proteins and regulates transcription. Overexpression of LSD1 drives the development of multiple cancers, such as prostate, breast, gastric, lung, colorectal cancers, and acute myeloid leukemia. Although several LSD1 inhibitors have shown promise for cancer therapy, monotherapy faces challenges such as low selectivity, high toxicity, and drug resistance. To overcome these drawbacks and achieve synergistic anticancer effects, researchers have focused on dual inhibitors that target LSD1 along with other oncogenic partners, including HDAC, EGFR, EZH2, tubulin, ERα, G9a, JmjC, DCN1, and SMOX. This review aims to provide recent design strategies and SAR for LSD1-based dual inhibitors, emphasizing the fusion of different LSD1 pharmacophore (tranylcypromine, pargyline, pyridine, 5-cyano-3-phenylindole, indole, benzyl/aryl piperazine, triazole-dithiocarbamate and substituted triazole scaffold) with various heterocyclic and zinc-binding cores such as hydroxamic acids, bipyridine, hydroxy quinoline to generate hybrids capable of inducing apoptosis, blocking cell-cycle, differentiation. This review explores the pharmacological role of LSD1 in oncogenesis and offers structural and SAR insights to guide the design of LSD1-based dual inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone DemethylasesAntineoplastic AgentsEnzyme InhibitorsNeoplasmsHumansStructure-Activity RelationshipAnimals

Stichwörter der Autor:innen

EGFREZH2HDACLSD1epigenetic

Substanzen

Histone DemethylasesAntineoplastic AgentsKDM1A protein, humanEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India.
  • Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India.

Zitieren

APA

Ghosh, P., Dhir, R., Sharma, D., Maity, S., Bharti, S. K., & Asati, V. (2026). LSD1-based dual-target inhibitors as emerging anticancer agents: pharmacological perspectives and SAR exploration. Future Medicinal Chemistry, 18(16), 2203-2225. https://doi.org/10.1080/17568919.2026.2699684

Vancouver

Ghosh P, Dhir R, Sharma D, Maity S, Bharti SK, Asati V. LSD1-based dual-target inhibitors as emerging anticancer agents: pharmacological perspectives and SAR exploration. Future Medicinal Chemistry. 2026;18(16):2203-2225. doi:10.1080/17568919.2026.2699684

BibTeX
@article{Ghosh2026,
  author = {Ghosh, Pitam and Dhir, Ryena and Sharma, Dinki and Maity, Subhadip and Bharti, Sanjay Kumar and Asati, Vivek},
  title = {LSD1-based dual-target inhibitors as emerging anticancer agents: pharmacological perspectives and SAR exploration},
  journal = {Future Medicinal Chemistry},
  year = {2026},
  volume = {18},
  number = {16},
  pages = {2203--2225},
  doi = {10.1080/17568919.2026.2699684}
}
Kostenlos starten →